หน้าแรก
ค้นหา
Upfront Ibrutinib: RESONATE-2 Trial
For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
แสดงข้อมูลเพิ่มเติม 1
Upfront Ibrutinib: RESONATE-2 Trial
Overview of the RESONATE-2 clinical trial of ibrutinib as front-line therapy
RESONATE-2: ibrutinib and chlorambucil for frontline CLL
RESONATE-2 trial of ibtrutinib in CLL
RESONATE-2 Trial: Safety and Efficacy Updates
Re-analysis of RESONATE-2 trial of ibrutinib vs chlorambucil in CLL
Ibrutinib as a frontline therapy in RESONATE2 trials for CLL
Late-Breaking Abstract: RESONATE 2 Finds First-Line Ibrutinib Superior to Chlorambucil in CLL/SLL
The RESONATE-2 Study
RESONATE-2 follow up: ibrutinib and chlorambucil 5 years on
Clinical Impact of the RESONATE-2 Trial in CLL
RESONATE-2: Five-year follow up of CLL patients receiving ibrutinib as first-line treatment
Dr. Brown on Lessons Learned From RESONATE-2 Trial for CLL
RESONATE, RESONATE-2 and HELIOS: three major clinical trials in CLL research
Clinical Significance of Upfront Ibrutinib in CLL
7-year follow-up of RESONATE-2 trial for CLL/SLL
Patient Selection for Upfront Ibrutinib
Outcomes from the RESONATE 2 and HELIOS Trials—Clinical Impact
Dr. Woyach Discusses the Efficacy Findings from the RESONATE Trial
Upfront Ibrutinib in CLL
